Psychedelic therapies are emerging as promising treatments for various mental health conditions, such as depression, post-traumatic stress disorder (PTSD), anxiety and substance-use disorders.
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...